UniQure Stock Plunges 12.55% Amid Regulatory Setbacks

On April 10, 2025, uniQure's stock price plummeted by 12.55% in pre-market trading, signaling a significant downturn for the biotechnology company.

UniQure, a leading gene therapy company, has been facing challenges in recent months. The company's stock has been under pressure due to regulatory setbacks and delays in clinical trials. These issues have raised concerns among investors about the company's ability to bring its innovative therapies to market in a timely manner.

Additionally, the company has been grappling with competition from other biotech firms, which has further intensified the pressure on its stock price. Despite these challenges, uniQure remains committed to advancing its gene therapy pipeline and addressing unmet medical needs.